Search Results | Journal of Experimental Medicine

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

In Special Collection:

JEM Cancer Immunotherapy 2022 , JEM Clinical Immunology Collection 2022 , Mechanisms and Models of Cancer 2022 Update

J Exp Med (2022) 219 (6): e20212169.

DOI: https://doi.org/10.1084/jem.20212169

Published: 23 May 2022

View article

Includes: Supplementary data

Journal Articles

Immigration in science

Jean-Laurent Casanova, David M. Holtzman, Susan M. Kaech, Lewis L. Lanier, Carl F. Nathan, Alexander Y. Rudensky, David Tuveson, Jedd D. Wolchok

J Exp Med (2020) 217 (11): e20202055.

DOI: https://doi.org/10.1084/jem.20202055

Published: 15 October 2020

View article

Journal Articles

The many faces of the anti-COVID immune response A review of the anti-COVID immune response

In Special Collection:

COVID-19: From Basic Science to Therapeutics

Santosha A. Vardhana, Jedd D. Wolchok

J Exp Med (2020) 217 (6): e20200678.

DOI: https://doi.org/10.1084/jem.20200678

Published: 30 April 2020

View article

Journal Articles

Selective inhibition of low-affinity memory CD8⁺ T cells by corticosteroids

Akihiro Tokunaga, Daisuke Sugiyama, Yuka Maeda, Allison Betof Warner, Katherine S. Panageas, Sachiko Ito, Yosuke Togashi, Chika Sakai, Jedd D. Wolchok, Hiroyoshi Nishikawa

J Exp Med (2019) 216 (12): 2701–2713.

DOI: https://doi.org/10.1084/jem.20190738

Published: 19 September 2019

View article

Includes: Supplementary data

Journal Articles

Shared cancer neoantigens: Making private matters public

In Special Collection:

Cancer 2018 , T Cell Dysfunction, Cancer, and Infection

Christopher A. Klebanoff, Jedd D. Wolchok

J Exp Med (2017) 215 (1): 5–7.

DOI: https://doi.org/10.1084/jem.20172188

Published: 21 December 2017

View article

Journal Articles

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

Aude G. Chapuis, Sylvia M. Lee, John A. Thompson, Ilana M. Roberts, Kim A. Margolin, Shailender Bhatia, Heather L. Sloan, Ivy Lai, Felecia Wagener, Kendall Shibuya, Jianhong Cao, Jedd D. Wolchok, Philip D. Greenberg, Cassian Yee

J Exp Med (2016) 213 (7): 1133–1139.

DOI: https://doi.org/10.1084/jem.20152021

Published: 30 May 2016

View article

Includes: Supplementary data

Journal Articles

Immunotherapy and the belly of the beast

Taha Merghoub, Jedd D. Wolchok

J Exp Med (2014) 211 (12): 2327–2328.

DOI: https://doi.org/10.1084/jem.21112insight3

Published: 17 November 2014

View article

Journal Articles

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

Tyler R. Simpson, Fubin Li, Welby Montalvo-Ortiz, Manuel A. Sepulveda, Katharina Bergerhoff, Frederick Arce, Claire Roddie, Jake Y. Henry, Hideo Yagita, Jedd D. Wolchok, Karl S. Peggs, Jeffrey V. Ravetch, James P. Allison, Sergio A. Quezada

J Exp Med (2013) 210 (9): 1695–1710.

DOI: https://doi.org/10.1084/jem.20130579

Published: 29 July 2013

View article

Journal Articles

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

In Special Collection:

2018 Nobel Prize Collection

Rikke B. Holmgaard, Dmitriy Zamarin, David H. Munn, Jedd D. Wolchok, James P. Allison

J Exp Med (2013) 210 (7): 1389–1402.

DOI: https://doi.org/10.1084/jem.20130066

Published: 10 June 2013

View article

Journal Articles

Induction of tumoricidal function in CD4⁺ T cells is associated with concomitant memory and terminally differentiated phenotype

Daniel Hirschhorn-Cymerman, Sadna Budhu, Shigehisa Kitano, Cailian Liu, Feng Zhao, Hong Zhong, Alexander M. Lesokhin, Francesca Avogadri-Connors, Jianda Yuan, Yanyun Li, Alan N. Houghton, Taha Merghoub, Jedd D. Wolchok

J Exp Med (2012) 209 (11): 2113–2126.

DOI: https://doi.org/10.1084/jem.20120532

Published: 24 September 2012

View article

Journal Articles

Hiding the road signs that lead to tumor immunity

David A. Schaer, Alexander M. Lesokhin, Jedd D. Wolchok

J Exp Med (2011) 208 (10): 1937–1940.

DOI: https://doi.org/10.1084/jem.20111856

Published: 26 September 2011

View article

Journal Articles

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

Daniel Hirschhorn-Cymerman, Gabrielle A. Rizzuto, Taha Merghoub, Adam D. Cohen, Francesca Avogadri, Alexander M. Lesokhin, Andrew D. Weinberg, Jedd D. Wolchok, Alan N. Houghton

J Exp Med (2009) 206 (5): 1103–1116.

DOI: https://doi.org/10.1084/jem.20082205

Published: 04 May 2009

View article

Includes: Supplementary data

Journal Articles

Self-antigen–specific CD8⁺ T cell precursor frequency determines the quality of the antitumor immune response

Gabrielle A. Rizzuto, Taha Merghoub, Daniel Hirschhorn-Cymerman, Cailian Liu, Alexander M. Lesokhin, Diana Sahawneh, Hong Zhong, Katherine S. Panageas, Miguel-Angel Perales, Grégoire Altan-Bonnet, Jedd D. Wolchok, Alan N. Houghton

J Exp Med (2009) 206 (4): 849–866.

DOI: https://doi.org/10.1084/jem.20081382

Published: 30 March 2009

View article

Includes: Supplementary data

Journal Articles

Coupling and Uncoupling of Tumor Immunity and Autoimmunity

Wilbur B. Bowne, Roopa Srinivasan, Jedd D. Wolchok, William G. Hawkins, Nathalie E. Blachere, Ruben Dyall, Jonathan J. Lewis, Alan N. Houghton

J Exp Med (1999) 190 (11): 1717–1722.

DOI: https://doi.org/10.1084/jem.190.11.1717

Published: 06 December 1999

View article

NARROW

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

Immigration in science

The many faces of the anti-COVID immune response A review of the anti-COVID immune response

Selective inhibition of low-affinity memory CD8⁺ T cells by corticosteroids

Shared cancer neoantigens: Making private matters public

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

Immunotherapy and the belly of the beast

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Induction of tumoricidal function in CD4⁺ T cells is associated with concomitant memory and terminally differentiated phenotype

Hiding the road signs that lead to tumor immunity

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

Self-antigen–specific CD8⁺ T cell precursor frequency determines the quality of the antitumor immune response

Coupling and Uncoupling of Tumor Immunity and Autoimmunity

Email alerts

Email alerts

This Feature Is Available To Subscribers Only